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Abstract. Background: The rate-limiting enzyme of the
mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme
A (HMG CoA) reductase, provides essential intermediates
for the prenylation or dolichylation of growth-related
proteins. d-δ-Tocotrienol, a post-transcriptional down-
regulator of HMG CoA reductase, suppresses the
proliferation of murine B16 melanoma cells. Dietary d-δ-
tocotrienol suppresses the growth of implanted B16
melanomas without toxicity to host mice. Materials and
Methods: The proliferation of human A2058 and A375
melanoma cells following a 72 h incubation in 96-well plates
was measured by CellTiter 96® Aqueous One Solution. Cell
cycle distribution was determined by flow cytometry.
Fluorescence microscopy following acridine orange and
ethidium bromide dual staining and procaspase-3 cleavage
were used to detect apoptosis. Western-blot was employed to
measure protein expression. Results: d-δ-Tocotrienol induced
dose-dependent suppression of cell proliferation with 50%
inhibitory concentrations (IC50) of 37.5±1.4 (A2058) and
22.3±1.8 (A375) μmol/l, respectively (data are reported as
mean±standard deviation). d-δ-Tocotrienol-mediated cell
cycle arrest at the G1 phase was accompanied by reduced
expression of cyclin-dependent kinase 4. Concomitantly, d-
δ-tocotrienol induced caspase-3 activation and apoptosis.
The impact of d-δ-tocotrienol on A2058 cell proliferation
was potentiated by lovastatin (IC50=3.1±0.5 μmol/l), a
competitive inhibitor of HMG CoA reductase. Conclusion:
d-δ-Tocotrienol may have potential application in melanoma
chemoprevention and/or therapy.
The mevalonate pathway provides essential intermediates,
namely farnesyl- and geranylgeranyl-pyrophosphates, for the
post-translational modifications and biological activities of
growth-related proteins including Ras (1), nuclear lamins (2)
and insulin-like growth factor I receptor (3) and supports cell
cycle progression and cell proliferation (4, 5). The
tocotrienols are vitamin E isomers that post-transcriptionally
down-regulate 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase activity, the rate-limiting activity of
the mevalonate pathway (4). A recent publication reviewed
the parallel impact of the tocotrienols and the statins,
competitive inhibitors of HMG CoA reductase, on cell cycle
progression, apoptosis, and cell proliferation consequent to
tocotrienol- and statin-mediated mevalonate deprivation (6). 
The dysregulation of HMG CoA reductase in tumors
offers a unique target for tumor suppression. Distinctive from
the multivalent regulation of the reductase activity consisting
of sterol-mediated transcriptional feedback inhibition and
non-sterol-mediated post-transcriptional ablation in
sterologenic tissues, tumor reductase is resistant to sterol-
feedback regulation but retains a unique sensitivity to the
non-sterol- and tocotrienol-mediated down-regulation. As a
consequence of the tocotrienol-mediated tumor-specific
suppression of reductase (7), tocotrienols suppress the
growth of cells isolated from breast, liver, prostate, skin,
colon, blood, lung, lymph gland, cervix and nerve tumors;
these actions are attributable to tocotrienol-mediated cell
cycle arrest and initiation of apoptosis. Dietary tocotrienols
suppress the growth of chemically initiated mammary, lung
and liver carcinogenesis, that of implanted melanoma,
prostate and mammary tumors and that of spontaneous liver
tumors (reviewed in (6)).
It was previously shown that d-γ-tocotrienol (8-10) and
the more potent d-δ-tocotrienol (8, 9) suppress the
proliferation of murine B16 melanoma cells. Cell cycle arrest
at the G1 phase and initiation of apoptosis contribute to the
impact of d-γ-tocotrienol (10). The growth of implanted B16
melanomas in mice was suppressed by dietary d-γ-
tocotrienol (9), and a blend of d-δ-tocotrienol and lovastatin
(8); the latter impact was synergistic. 
The current study evaluated the impact of d-δ-tocotrienol,
the tocotrienol with the highest tumor-suppressive activity
among the tocotrienol isomers (8), on the proliferation of
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human A375 malignant melanoma cells and A2058
metastatic melanoma cells. In both cell lines, d-δ-tocotrienol
mediated concentration-dependent suppression of the
proliferation, which was accompanied by cell cycle arrest at
the G1 phase and initiation of apoptosis. Lovastatin
potentiated the d-δ-tocotrienol-mediated growth suppression.
Materials and Methods
Chemicals. Lovastatin and d-δ-tocotrienol were gifts from Merck
Research Laboratories (Rahway, NJ, USA) and American River
Nutrition, Inc. (Hadley, MA, USA), respectively. 
Cell proliferation assay. Human melanoma cell proliferation was
measured by using CellTiter 96® Aqueous One Solution (Promega,
Madison, WI, USA) as previously described (11). Briefly, A375 and
A2058 melanoma cells, obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) modified by ATCC to contain 4
mM L-glutamate, 1.5g/l sodium bicarbonate, and 4.5 g/l glucose and
supplemented with 10% fetal bovine serum (FBS; Hyclone Lab Inc.,
Logan, UT, USA) and 1% penicillin-streptomycin (MP Biomedicals,
Solon, OH, USA) at 37˚C in a humidified atmosphere of 5% CO2, were
seeded at 3,000 cells/0.1 ml medium/well in 96-well tissue culture
plates (Fisher Scientific Company LLC, Houston, TX, USA). At 24 h,
the medium was decanted from each well and replaced with 0.1 ml
fresh medium containing d-δ-tocotrienol and lovastatin that were pre-
dissolved in ethyl alcohol and dimethyl sulfoxide (DMSO),
respectively. All cultures including the controls contained 1 ml/l of ethyl
alcohol or DMSO. Cells were incubated for additional 72 h. The 96-h
cell populations were determined by adding 20 μl of CellTiter 96®
Aqueous One Solution to each well; plates were placed in the dark at
37˚C for 2 h then read at 490 nm with a SPECTRAmax® 190 multi-
plate reader with SOFTmax® PRO version 3.0 (Molecular Devices,
Sunnyvale, CA, USA). Absorbances from wells containing cell-free
medium were used as baselines and deducted from absorbances of
other cell-containing wells. The IC50 value was determined as the
concentration of an agent required to suppress the net increase in cell
number by 50%.
Microscopy. Photomicrographs of representative fields of monolayers
of melanoma cells were produced with a Nikon Eclipse TS 100
microscope (Nikon Corporation, Tokyo, Japan) equipped with a
Nikon Coolpix 995 digital camera (Nikon Corporation).
Cell cycle analysis. A375 and A2058 cells were seeded in 75 cm2
flask (Becton Dickinson Labware, Franklin Lakes, NJ, USA) at 3×106
cells/flask with 10 ml medium/flask and incubated for 24 h. Medium
was then decanted and cultures replenished with medium containing
d-δ-tocotrienol or lovastatin. Following additional 48 h incubation,
adherent cells were harvested by trypsinization and pelleted by low
speed centrifugation. Cell pellets were fixed in 70% ethanol (1×106
cells/ml) at 4˚C overnight, washed in 1 ml phosphate-buffered saline
(PBS) and re-suspended in 500 μl PBS containing 0.5 mg RNase A
(Sigma, St. Louis, MO, USA) at 37˚C for 30 min. Following gentle
mixing, 500 μl PBS and 100 μl aliquot of propidium iodide (Sigma,
1 g/l in PBS containing 0.1% Triton X-100) were added. The cells
were incubated in the dark at room temperature for 15 min and then
placed in the dark at 4˚C for flow cytometric analysis. Aliquots of
1×104 cells were analyzed for DNA content using a BD
FACSCaliber™ Flow Cytometer (BD Biosciences, San Jose, CA,
USA). The distribution of cells in the G1, S, and G2/M phases of the
cell cycle was determined using MultiCycle AV software (Phoenix
Flow Systems, San Diego, CA, USA).
Acridine orange and ethidium bromide dual staining assay for
apoptosis. A375 cells were inoculated in 6-well plates with 3 ml
medium and 6×104 cells per well. Following a 48 h incubation with
d-δ-tocotrienol, a dye mixture (15 μl) containing 50 μg/ml acridine
orange (Becton, Dickinson and Company, Sparks, MD, USA) and
50 μg/ml ethidium bromide (Sigma) was added to each well.
Following a 1 min staining, the cells were observed under an
Observer Z1 microscope (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY, USA) equipped with a X-CITE® series 120 Q
lamp, an AxioCam MRm digital camera system and an AxioVision
Rel. 4.7 program (all from Carl Zeiss MicroImaging, Inc.). The
phase-contrast images of representative fields of each well and the
green and red fluorescence emitted by acridine orange and ethidium
bromide staining were captured by using bright field phase 2,
fluorescein isothiocyanate and tetramethylrhodamine isothiocyanate
filters, respectively.
Western blot. Human A375 and A2058 melanoma cells cultured in
175 cm2 flasks (BD Bioscience, Bedford, MA, USA) at 1.5×106
cells per flask were incubated with d-δ-tocotrienol for 48 h.
Following the incubation, the growth medium was aspirated and
cells washed with 15 ml ice-cold PBS twice, harvested by
trypsinization, centrifuged and counted; 150 μl of Laemmli buffer
(Bio-Rad, Hercules, CA, USA) with 1% protease inhibitor cocktail
(Sigma) freshly mixed was then added to pellets of 1.0×106 cells.
Cells were subjected to homogenization for 45 s and placed in a dry
bath incubator (Boekel Scientific, Feasterville, PA, USA) at 90°C
for 20 min. Protein concentration of each sample was determined
with Pierce 660 nm Protein Assay Reagent mixed with Ionic
Detergent Compatibility Reagent (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions. Samples containing 40
μg proteins were mixed with β-mercaptoethanol (1:20) and boiled
for 5 min before being loaded onto a Mini PROTEAN® 3 (Bio-Rad)
electrophoresis unit with a 15% SDS-polyacrylamide gel and run at
150 V for 2-4 h. The proteins were then transferred to Immobilon-
P transfer membrane (Millipore, Bedford, MA, USA) with a Trans-
Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad) at 10 V
for 2 h or a Mini Trans-Blot® Cell (Bio-Rad) at 100 mA overnight.
The immobilon-P transfer membranes were then incubated in
blocking solution (5% fat-free dry milk in PBS containing 0.1%
Tween-2; PBST) for 2 h at 4˚C with shaking, rinsed with PBS, and
then incubated with monoclonal antibodies to cyclin-dependent
kinase (Cdk) 4 (Cell Signaling Technology, Beverly, MA, USA),
procaspase-3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), and Ras (Cell Signaling Technology) at 4˚C overnight. After
rinsing with PBST for 10 min, the membrane was incubated with a
secondary antibody (horseradish peroxidase linked; Cell Signaling
Technology; 1:3,000 in PBST) for 20 min at room temperature,
washed with PBST for 15 min, and reacted with SuperSignal West
Pico Chemiluminescence Kit (Pierce) before being photographed at
Chemi Doc XRS imaging system (Bio-Rad). Precision Strep Tactin-
HRP (Bio-Rad) protein standards were used to identify the
molecular weight of protein bands. A non-specific IgG (Cell
Signaling Technology) was used for background control.
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Statistics. One-way analysis of variance (ANOVA) was performed
to assess the differences between groups using Prism 4.0 (GraphPad
Software Inc., San Diego, CA, USA). Differences in means between
control and treatment groups were analyzed by Dunnett’s test.
Levels of significance were designated as p<0.05. Data are reported
as the mean±standard deviation of three experiments.
Results
d-δ-Tocotrienol and lovastatin (Figure 1A) elicited a
concentration-dependent suppression of the proliferation of
human A2058 and A375 melanoma cells. A375 cells were
more sensitive than A2058 cells to d-δ-tocotrienol- and
lovastatin-mediated growth suppression. The IC50 values for
d-δ-tocotrienol were 22.3±1.8 (A375) and 37.5±1.4 (A2058)
μM, respectively. Lovastatin with IC50 values of 0.5±0.1
(A375) and 3.1±0.5 (A2058) μM, respectively, was more
potent than d-δ-tocotrienol in growth suppression. 
The d-δ-tocotrienol-mediated growth suppression was
accompanied by morphological changes. Photomicrographs
of A2058 (Figure 1B, I - III) and A375 (Figure 1B, IV - VIII)
melanoma cells incubated with d-δ-tocotrienol showed a
concentration-dependent decrease in cell density, nuclear
condensation, membrane blebbing and cell detachment from
the monolayer; characteristics reminiscent of apoptosis. Cells
remaining on the monolayer were harvested for cell cycle
analysis because previous studies suggested that d-δ-
tocotrienol-mediated cell cycle arrest contributes to d-δ-
tocotrienol-mediated growth suppression (11). Following a
48 h incubation with 24 μM (2/3 × IC50 value) of d-δ-
tocotrienol and 3 μM (IC50 value) of lovastatin, the
percentages of cells in the G1 phase reached 63.3±1.2% and
59.5±0.2%, respectively, both significantly (p<0.01) higher
than that of control cells (46.7±1.2%) (Table I).
Concomitantly, the percentages of cells in the S phase
reached 20.3±0.9% and 22.4±1.7% for cells incubated with
d-δ-tocotrienol and lovastatin, respectively; both values were
significantly (p<0.01) lower than that of the control cells
(35.1±1.1%). The G1/S ratio, an indicator of G1 arrest, for
cells incubated with d-δ-tocotrienol (3.1±0.2) and lovastatin
(2.7±0.2) were 135% (p<0.01) and 100% (p<0.01),
respectively, higher than that for the control cells (1.3±0.1%).
The d-δ-tocotrienol- and lovastatin-mediated cell cycle arrest
at the G1 phase was also shown in A375 cells. Following a
48 h incubation with 33 μM (1.5 × IC50 value) of d-δ-
tocotrienol and 0.5 μM (IC50 value) of lovastatin, the G1/S
ratio was increased to 2.7±0.3 and 2.7±0.2, respectively,
significantly (p<0.05) higher than that of the control cells
(2.1±0.3). The G1 arrest induced by d-δ-tocotrienol was
accompanied by a decreased expression of Cdk4 (Figure 2),
a key regulator in the G1/S transition (12). Following a 48 h
incubation with 38 μM (A2058) or 33 μM (A375) d-δ-
tocotrienol, the intensity of Cdk4 protein band decreased
significantly in comparison to the control. 
Previous studies have shown that d-δ-tocotrienol-induced
apoptosis, suggested in the photomicrographs of A2058 and
A375 cells (Figure 1B), often accompanies cell cycle arrest
in mediating growth suppression (6, 11). Therefore, first the
impact of d-δ-tocotrienol on apoptosis was examined in
A375 cells using acridine orange and ethidium bromide dual
staining and fluorescence microscopy. Viable cells have
acridine orange staining with normal cell morphology.
Acridine orange- and ethidium bromide-stained cells with
condensed nucleus are in early and late apoptosis stages,
respectively (11). In representative fields of view of the same
size, the total number of A375 cells following a 48 h
incubation with 33 μM/l of d-δ-tocotrienol (Figure 3A, V-
VIII) was lower than that of control cells (Figure 3A, I-IV),
most clearly shown in phase-contrast images (Figure 3A, I
and V); nevertheless, the total number and percentage of
A375 cells with ethidium bromide staining emitting red
fluorescence increased (Figure 3A, III and VII). 
d-δ-Tocotrienol-induced apoptosis was confirmed by
Western blot of procaspase-3 cleavage in A2058 cells (Figure
3B). d-δ-Tocotrienol initiated a concentration-dependent
cleavage of procaspase-3 in A2058 cells as evidenced by the
gradual decrease in the procaspase-3 protein following a 48
h incubation with 19 and 38 μM d-δ-tocotrienol, despite a
constant amount of total protein loading indicated by the β-
actin band. 
A key protein that plays important roles in melanoma
growth and one that may be impacted by the tocotrienol-
mediated down-regulation of the mevalonate pathway
activity is the oncogenic Ras protein that undergoes a
farnesylation process (13). The finding that α-tocotrienol
down-regulates the expression of Ras in human A549 lung
carcinoma cells (14) and the fact that 20% of human
melanomas harbor Ras mutation (15) prompted the
evaluation of the impact of d-δ-tocotrienol on total cellular
Ras protein. As shown in Figure 4, 33 μM and 38 μM d-δ-
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Table I. The impact of d-δ-tocotrienol and lovastatin on the 48-h cell
cycle distribution of human A2058 and A375 melanoma cells. Values
represent the mean±standard deviation of three experiments.
G1 (%) S (%) G2 (%) G1/S
A2058
Control 46.7±1.2 35.1±1.1 18.1±1.1 1.3±0.1
d-δ-Tocotrienol (24 μM) 63.3±1.2* 20.3±0.9* 16.3±0.8 3.1±0.2*
Lovastatin (3 μM) 59.5±0.2* 22.4±1.7* 18.1±1.6 2.7±0.2*
A375
Control 59.2±2.9 28.9±2.1 11.9±1.0 2.1±0.3
d-δ-Tocotrienol (33 μM) 65.7±1.0* 24.3±2.4 10.0±1.5 2.7±0.3#
Lovastatin (0.5 μM) 64.5±1.1# 24.1±1.5# 11.4±0.3 2.7±0.2#
*p<0.01; #p<0.05.
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Figure 1. d-δ-Tocotrienol- and lovastatin-mediated suppression of the proliferation of human A375 and A2058 melanoma cells. A: Representative
growth curves of human A375 () and A2058 ( melanoma cells showing the concentration-dependent suppression of cell proliferation by d-δ-
tocotrienol and lovastatin. Cells were cultured and incubated with the compounds for 72 h before cell proliferation was measured by CellTiter 96®
Aqueous One Solution as described in the Materials and Methods. Values represent the mean±standard deviation of four experiments. B: The
concentration-dependent inhibition of human A2058 and A375 melanoma cell proliferation shown in photomicrographs of A2058 (I-III) and A375
(IV-VIII) cells following a 72-h incubation with 0 (I and IV), 30 (II), 60 (III), 11 (V), 22 (VI) and 33 (VII) μmol/l d-δ-tocotrienol and 0.75 μmol/l
lovastatin (VIII). The contact inhibition-disabled growth of the A2058 and A375 cells is shown in the control cultures (I and IV). Concentration-
dependent decreases in cell density and changes in cell morphology occurred progressively as the concentration of d-δ-tocotrienol increased. Arrows
mark indicators of apoptotic cell death (nuclear condensation and membrane blebbing) and changes in cell morphology.
tocotrienol decreased the expression of Ras protein in A375
and A2058 cells, respectively, following a 48 h incubation. 
The IC50 values of d-δ-tocotrienol for the human melanoma
cells, and particularly that for the A2058 cells, fall in the high
end of the physiologically attainable peak plasma levels of d-
δ-tocotrienol following oral administration (16). Previous
studies have shown the synergy obtained with blends of d-δ-
tocotrienol and lovastatin in suppressing the growth of murine
B16 melanoma cells (8) and human MIA PaCa-2 pancreatic
carcinoma cells (11). Next, the potential synergistic impact of
these two agents on the more resistant A2058 cells was
evaluated (Table II). The net growth of A2058 cells incubated
with 24 μM of d-δ-tocotrienol and 1.5 μM of lovastatin for 72
h were 89±7% and 70±13%, respectively, of that of the control
cells. A blend of the two agents suppressed cell growth by
79%, doubling the predicted impact suggested by the sum
(41%) of individual actions. Synergy was also shown with a
blend containing 24 μM of d-δ-tocotrienol and a higher (3
μM) but still physiologically attainable concentration (17) of
lovastatin; the blend suppressed cell growth by 97%, far
exceeding the predicted impact suggested by the sum (61%)
of individual actions.
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Figure 2. The impact of d-δ-τocotrienol on the expression of Cdk4
protein in human A2058 and A375 melanoma cells following a 4-h
incubation. Cell lysates were subjected to Western blot procedures and
blots were detected by chemiluminescence. Representative blots from
four experiments are shown.
Figure 3. d-δ-Tocotrienol-mediated apoptosis in A375 (A) and A2058
(B). A: Photomicrographs of human A375 melanoma cells showing the d-
δ-tocotrienol-initiated apoptosis detected by acridine orange and
ethidium bromide dual staining. A375 cells were incubated with 0 (I-IV)
and 33 (V-VIII) μM d-δ-tocotrienol for 48 h. Photomicrographs of the
same fields were taken under phase-contrast microscope (I and V) and
fluorescence microscope with a tetramethylrhodamine isothiocyanate (II
and VI) or fluorescein isothiocyanate filter (III and VII) and then merged
(IV and VIII). Arrows mark the red fluorescence emitted by ethidium
bromide staining shown in late apoptotic and dead cells induced by d-δ-
tocotrienol. B: The impact of d-δ-tocotrienol on the cleavage of
procaspase-3 in human A2058 melanoma cells following a 48 h
incubation. Cell lysates were subjected to Western blot procedures and
blots were detected by chemiluminescence and quantitated.
Representative blots from three experiments are shown.
Table II. Synergistic effect of d-δ-tocotrienol and lovastatin on the growth
of human A2058 melanoma cells. Values represent the mean±standard





d-δ-Tocotrienol (24 μM) 89±7a
Lovastatin (1.5 μM) 70±13ab
Lovastatin (3 μM) 50±12ab
d-δ-Tocotrienol (24 μM)+lovastatin (1.5 μM) 21±4ab
d-δ-Tocotrienol (24 μM)+lovastatin (3 μM) 3±1b
Discussion
Building on the previous observation of the anti-proliferative
activity of d-δ-tocotrienol (IC50=10-14 μM) in murine B16
melanoma cells (8, 9), the present study demonstrated the
growth-suppressive activity of d-δ-tocotrienol, albeit with
higher IC50 values, in two human melanoma cell lines. A
recent study (18) with two human amelanotic and melanotic
malignant melanoma cells, C32 and G361, and a shorter 24
h treatment period suggested IC50 values in the range of 40-
60 μM, consistent with the IC50 value for the A2058 cells.
The IC50 value for lovastatin in A375 cells (0.5 μM) was
lower than that reported by Shellman et al. ( approximately,
2.8 μM) (19); modulating factors such as inoculating cell
density (20) and assay methodology (21) may have
contributed to such a difference. Nevertheless, the IC50 value
for lovastatin in A2058 cells fell in the interval of reported
IC50 values for human melanoma cell lines WM35,
WM1552C, WM75, WM115, WM278, A375, WM1617,
WM852, WM239A, HS294T (19), 1011 (22), SK-MEL-2
(23), HT144, M14, and SK-MEL-28, ranging from 1.2 μM
to 30 μM (24).
Consonant with its impact on cell cycle distribution noted
in previous studies with human pancreatic tumor cells (11),
d-δ-tocotrienol effected cell cycle arrest at the G1 phase in
A375 and A2058 cells. The loss of Cdk4 expression
resembles the impact of d-δ-tocotrienol shown in MDA-MB-
231 breast cancer cells (25). G1 arrest was also noted in
murine B16 melanoma cells incubated with a less potent (8)
d-γ-tocotrienol (10), which, in a recent report (18),
purportedly failed to induce G1 arrest in human C32 and
G361 melanoma cells; the latter may be masked by a
massive d-γ-tocotrienol-induced sub-diploid peak, an
indicator of apoptosis (26) that was confirmed by the
activation of caspases 3, 7 and 9 and the cleavage of poly
(ADP-ribose) polymerase (PARP) (18). Consistent with its
apoptotic activity shown in the human pancreatic tumor cells
(11), d-δ-tocotrienol induced apoptosis in A375 and A2058
cells as shown by acridine orange and ethidium bromide dual
staining and procaspase-3 cleavage; apoptosis and caspase-3
activation were also shown in lovastatin-treated A375 cells
(19).
The Raf/mitogen-activated protein kinase (MAPK)/
extracellular signal regulated kinase (ERK) kinase (MEK)/
ERK/nuclear factor kappa B (NF-κB) and phosphoinositide 3-
kinase (PI3K)/Akt/NF-κB pathways control cell cycle
progression, up-regulation of Cdk4 (27), apoptosis and
differentiation. The Ras protein (28) that plays critical roles in
these pathways require mevalonate-derived farnesyl
pyrophosphate for its post-translational modification and
maturation (13). Ras mutation, mostly N-Ras mutation, is
found in about 20% of human melanoma (15). Lovastatin has
been shown to decrease Ras prenylation (3) and membrane
attachment (29) in human melanomas. Consistent with a
previous observation that α-tocotrienol and a tocotrienol
analog, 6-O-carboxypropyl-α-tocotrienol, inhibit the
prenylation of Ras and reduce the level of Ras protein in
human A549 lung carcinoma cells (30), d-δ-tocotrienol was
shown to reduce Ras protein levels in A375 and A2058 cells
(Figure 4). The decreased Ras protein expression likely reflects
the dislodgment and enhanced degradation of unprenylated
Ras, as seen in cells treated with farnesyl transferase inhibitors
(FTIs) (31-33). The half-lives of total Ras decreased from >12
h in untreated human PANC-1 pancreatic carcinoma cells to 7-
8 h in FTI-treated cells (31); FTI also reduced the half-life of
H-Ras from 27 h to 10 h in H-Ra-transformed Rat1 cells (32).
d-Limonene (1) and perillyl alcohol, the mevalonate-
suppressive monoterpenes, decrease Ras protein expression;
perillyl alcohol effected such a decrease in human myeloid
THP-1 and lymphoid RPMI-8402 leukemia cells (34, 35),
human SW480 colonic adenocarcinoma cells (36), human
K562 erythroleukemia cells (37) and 1984-1 melanoma cells
(33). More studies are needed to delineate whether Ras
degradation directly contributes to the d-δ-tocotrienol-mediated
growth suppression in A375 (38) and A2058 (39) cells with a
wild-type N-Ras. The finding that lovastatin-mediated
suppression of A375 cell proliferation was reversed by
supplemental geranylgeranyl pyrophosphate but not by farnesyl
pyrophosphate (19) that is required for Ras prenylation
suggests a Ras-independent mechanism for the HMG CoA
reductase suppressors. Rac1, a member of the Rho GTPases
and a downstream intermediate of Ras, mediates the malignant
phenotypes of skin tumor cells (40); functional Rac1 requires
geranylgeranylation (41). Other proteins including nuclear
lamins and insulin-like growth factor I receptor that are post-
translationally modified by mevalonate-derived intermediates,
may also mediate the tocotrienol effect.
ANTICANCER RESEARCH 30: 4937-4944 (2010)
4942
Figure 4. Representative blots showing the impact of d-δ-tocotrienol on
the expression of Ras in human A375 and A2058 melanoma cells
following a 48h incubation. Cell lysates were subjected to Western-blot
procedures and blots were detected by chemiluminescence.
Representative blots from four experiments are shown.
The IC50 values of d-δ-tocotrienol for A375 and A2058
cells approached the high end of physiologically attainable
peak plasma levels reported in one oral feeding study (16),
but far exceed that reported in another study (42).
Nevertheless, tocotrienols were found in high concentrations
in the skin in feeding studies (43, 44). In addition, the
parallel impacts of d-δ-tocotrienol, a post-translational
down-regulator of HMG CoA reductase and lovastatin, a
competitive inhibitor of reductase, on growth, cell cycle,
apoptosis and Ras protein noted in the present and other
studies (5, 8, 10, 11) and the same order of sensitivity of the
A375 and A2058 cells in responding to these two agents,
suggest the essentiality of the mevalonate pathway. The
synergy between d-δ-tocotrienol and lovastatin (Table II) is
consistent with prior observations in B16 melanoma cells
(10), human DU145 prostate carcinoma cells (5), MIA PaCa-
2 pancreatic carcinoma cells (11), and A549 lung carcinoma
cells (8), murine mammary tumor cells (45) and implanted
B16 tumors (8), suggesting that physiologically attainable d-
δ-tocotrienol and lovastatin (17) may be effective in
melanoma treatment or prevention. Isoprenoids with lesser
mevalonate-suppressive activity than d-δ-tocotrienol such as
citral (46), geraniol (47), β-ionone (9) and d-γ-tocotrienol
(9), suppress the growth of implanted and chemically
initiated melanomas. Blends of d-δ-tocotrienol and assorted
mevalonate suppressors may provide a novel approach in the
chemoprevention and/or therapy of melanomas.
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